What Strong Healthcare Due Diligence Actually Looks Like

Healthcare due diligence is sometimes treated as a slightly more technical version of ordinary venture diligence. In practice it is a different discipline. A healthcare company does not succeed simply because the product is clever, the market sounds large, or the founder tells a compelling story. It succeeds if the product fits real clinical or operational workflows, aligns with incentives, can be adopted by institutions under pressure, and creates value for a specific buyer in a way that can be proven over time. Strong diligence therefore has to move beyond enthusiasm, generalized category excitement, and broad TAM slides. It has to answer the harder question: does this business actually work in the environments it is trying to serve?

The first test is whether the problem is real enough to compel action. Many startups describe a problem that clinicians agree is frustrating, but that frustration may not be severe enough for a health system, payer, or employer to spend money and tolerate change. In healthcare, "important" and "fundable" are not the same thing. The pain has to belong to someone with budget, urgency, and authority. Good diligence asks who owns the problem, how often the problem shows up, how expensive it is to ignore, and why the timing is right for a buyer to care now rather than later.

The second test is workflow fit. Even technically strong products fail if they create too much friction for physicians, nurses, administrators, or patients. A company may demonstrate impressive performance in a pilot yet still struggle if implementation requires too many clicks, too much training, too many approvals, or too much dependence on one internal champion. We look carefully at where the product sits in the day-to-day reality of care delivery. Who touches it? Who resists it? What part of the process becomes easier, faster, safer, or more profitable? In healthcare, workflow is often the hidden determinant of whether the product becomes sticky or stalled.

Economic logic is the third test, and it is usually more nuanced than founders expect. A product can create clinical value without creating enough financial value for a buyer to move. A company needs a clear answer to what the customer gets in return for implementation risk, organizational attention, and budget allocation. That value may come from revenue generation, margin protection, labor savings, reduced denials, improved throughput, quality metrics, patient retention, or strategic differentiation. The mechanism matters. The time to value matters. The stakeholder who benefits first matters. We view reimbursement not as a narrow technical issue but as part of the broader economic architecture of the business.

Regulatory and evidence questions also have to be grounded in strategy rather than treated as checklist items. It is not enough for a company to say it can probably achieve FDA clearance or that studies will be done later. We want to understand whether the regulatory pathway, evidence plan, and commercial claims actually fit together. A business can be technically correct about its classification and still be strategically naive about how long evidence generation will take or what standard of proof the market will require. In healthcare and life sciences, that mismatch can be fatal. Strong diligence therefore connects regulatory planning, evidence development, capital needs, and go-to-market sequencing into one coherent view.

Finally, good diligence is about management judgment. We care less about perfect polish than about whether the team sees the market clearly. Do the founders understand the institutional complexity they are entering? Can they explain what remains unproven? Do they distinguish enthusiasm from adoption, pilots from scalable demand, and scientific interest from commercial readiness? The best healthcare diligence feels like operational stress-testing. It does not eliminate uncertainty, but it makes clear which uncertainties matter most and whether the company has a credible way through them. That is where conviction begins.